Enlivex (ENLV) Cost of Revenue (2022 - 2025)
Enlivex (ENLV) posted Cost of Revenue of $2.2 million for Q3 2025, up 18.04% on a QoQ basis from $1.9 million in Q2 2025, and down 15.26% year-over-year from $2.6 million in Q3 2024.
Analysis
Enlivex (ENLV) Cost of Revenue (2022 - 2025) Analysis & Trends
Enlivex has reported Cost of Revenue for 4 years, with the latest figure at $2.2 million in Q3 2025.
- On a quarterly basis, Cost of Revenue fell 15.26% year-over-year to $2.2 million in Q3 2025; TTM through Sep 2025 was $10.1 million, a 35.91% decrease from a year earlier, with the FY2022 full-year figure at $2.0 million, up 35.81% from the prior year.
- Cost of Revenue was $2.2 million for Q3 2025 at Enlivex, up from $1.9 million in the prior quarter.
- The five-year high for Cost of Revenue was $9.9 million in Q2 2022, with the low at -$21.8 million in Q4 2022.
- Average Cost of Revenue over 4 years is $3.0 million, with a median of $4.1 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Cost of Revenue advanced 4.01% in 2023, then sank 56.36% in 2024.
- Over 4 years, Cost of Revenue stood at -$21.8 million in 2022, then soared by 127.32% to $6.0 million in 2023, then tumbled by 56.36% to $2.6 million in 2024, then declined by 15.26% to $2.2 million in 2025.
- The last three Cost of Revenue figures came in at $2.2 million (Q3 2025), $1.9 million (Q2 2025), and $3.5 million (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.81 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.58 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 489.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 360.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 145.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 93.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 776.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 284,000.00 |
| 10 | Enlivex | 3.17 Mn | -2.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Sep 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 4.14 Mn |
| Sep 30, 2023 | 5.96 Mn |
| Jun 30, 2023 | 6.79 Mn |
| Mar 31, 2023 | 7.22 Mn |
| Dec 31, 2022 | -21.83 Mn |
| Sep 30, 2022 | 5.73 Mn |
| Jun 30, 2022 | 9.91 Mn |
| Mar 31, 2022 | 8.23 Mn |